Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

NCT00074646 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Malignant Gliomas

Interventions

DRUG: CC-8490

Sponsor

Celgene Corporation